

## Special Issue

# Zebrafish-Based Drug Screening

### Message from the Guest Editors

*Danio rerio*, a small teleost commonly known as zebrafish, has emerged as a powerful model organism for studying a wide variety of human diseases over the last few decades due to its small size, high fecundity, and genetic and genomic similarity to humans. Especially phenotype-based zebrafish testing, the so-called “zebrafish screening”, has been actively utilized to identify drug target molecules and therapeutic compounds in combination with various high-throughput technological innovations, such as high-content imager, large-scale behavior analysis, robotics, and bioinformatics. This Special Issue is intended to provide a forum to discuss zebrafish screening from broader perspectives, ranging from the creation of human diseases models, technologies harnessing these as a model organism, and their uses for drug discovery. Review articles by experts in the field would be particularly welcome.

### Guest Editors

Prof. Dr. Yasuhito Shimada

Department of Integrative Pharmacology, Mie University Graduate School of Medicine, Tsu, Mie, Japan

Prof. Dr. Herman P. Spalink

Animal Sciences and Health, Institute of Biology Leiden (IBL), Leiden University, 2333CC Leiden, The Netherlands

### Deadline for manuscript submissions

closed (30 September 2020)



## Molecules

an Open Access Journal  
by MDPI

Impact Factor 4.6  
CiteScore 8.6  
Indexed in PubMed



[mdpi.com/si/31370](https://mdpi.com/si/31370)

*Molecules*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[molecules@mdpi.com](mailto:molecules@mdpi.com)

[mdpi.com/journal/  
molecules](https://mdpi.com/journal/molecules)





# Molecules

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.6  
Indexed in PubMed



[mdpi.com/journal/  
molecules](https://mdpi.com/journal/molecules)



## About the Journal

### Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

---

### Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

#### Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).